From the Akebia website..
“The combined company brings together Keryx, a commercial organization, with Akebia, a leader in the development of HIF-PHI therapeutics for patients with kidney disease. The combined company will have an established renal development, manufacturing and commercial organization, and plans to leverage its leadership’s extensive expertise in the commercial renal market with the goal of maximizing sales of Auryxia while driving launch momentum for vadadustat in the United States, subject to its regulatory approval. Keryx’s established U.S. sales and marketing organization and its medical affairs team have built strong awareness within the nephrology community to address the needs of patients with CKD, and will drive the launch preparation and execution for vadadustat in the United States, subject to its regulatory approval.”
______________________
So Keryx brings to the table established renal development, manufacturing, and commercial organization.
Keryx brings to the table established U.S. sales & marketing and medical affairs team which has built strong awareness within the nephrology community.
Keryx will drive the launch preparation and execution for vadadustat in the United States, subject to its regulatory approval.
Keryx brings to the table twice FDA approved and EU approved blockbuster potential Auryxia well into commercialization in the U.S. with potential revenues in 2018 of $100 million plus.
What does AKBA bring to the table?
Yet KERX shareholders are being swindled out of 62.57% of their holdings, allowing for a “cooked-up pro forma baluation which ends-up giving ABKA nearly equal equity weight as KERX i.e. KERX 50.6% AKBA 49.4%.
If that isn’t the CFs of all CFs for KERX shsreholders then don’t know what is..
ALL IMO
